Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00346216
Status:
COMPLETED
Last Update Posted:
2021-03-03
First Post:
2006-06-28
Brief Title:
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A Randomized Double Blind Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRECISION
Brief Summary:
To answer the question of overall benefit risk of celecoxib when compared to two most commonly prescribe traditional non-selective nonsteroidal anti-inflammatory drugs NSAIDs in the treatment of arthritis pain For this purpose patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited The cardiovascular gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PRECISION TRIAL | OTHER | Alias Study Number | None |
| 2004-002441-13 | EUDRACT_NUMBER | None | None |